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Abstract
ADAM 17 (TNF-a converting enzyme, TACE) is a potential target for cancer therapy, but the small molecule inhibitors
reported to date are not specific to this ADAM family member. This membrane-bound metalloproteinase is responsible for
ectodomain shedding of pathologically significant substrates including TNF-a and EGFR ligands. The aim of this study was
to evaluate the pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the first specific inhibitor, an anti-human
ADAM17 IgG antibody, clone D1(A12). We used intraperitoneal xenografts of the human ovarian cancer cell line IGROV1-Luc
in Balb/c nude mice, chosen because it was previously reported that growth of these xenografts is inhibited by knock-down
of TNF-a. In vitro, 200 nM D1(A12) inhibited shedding of ADAM17 substrates TNF-a, TNFR1-a, TGF-a, amphiregulin (AREG),
HB-EGF and IL-6Ra, from IGROV1-Luc cells, (4.7 nM IC50 for TNF-a shedding). In IGROV1-Luc xenografts in vivo, D1(A12) IgG
showed pharmacokinetic properties suitable for efficacy studies, with a single i.p. dose of 10 mg/kg D1(A12) sufficient to
maintain IgG plasma and ascites fluid concentrations above 100 nM for more than 7 days. The plasma half life was 8.6 days.
Next, an efficacy study was performed, dosing D1(A12) or anti-human TNF-a antibody infliximab at 10 mg/kg q7d,
quantifying IGROV1-Luc tumour burden by bioluminescence. D1(A12) IgG showed a significant reduction in tumour growth
(p = 0.005), 56% of vehicle control. Surprisingly, D1(A12) did not reduce the concentration of circulating human TNF-a,
suggesting that another enzyme may compensate for inhibition of ADAM17 in vivo (but not in vitro). However, D1(A12) did
show clear pharmacodynamic effects in the mice, with significant inhibition of shedding from tumour of ADAM17
substrates TNFR1-a, AREG, and TGF-a (4–15-fold reductions, p,0.0001 for all three). Thus, D1(A12) has anti-ADAM17 activity
in vivo, inhibits shedding of EGFR ligands and has potential for use in EGF ligand-dependent tumours.
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Introduction
TNF-a converting enzyme (TACE, ADAM17) is a membrane-
bound metalloproteinase responsible for cleavage and ectodomain
shedding of TNF-a, EGFR ligands and other pathologically
significant substrates. Dysregulation of ectodomain shedding is
associated with autoimmune and cardiovascular diseases, neuro-
degeneration, infection, inflammation and cancer [1].
ADAM17 has been implicated in many cancers. It is
overexpressed in ovarian cancer [2], breast cancer [3,4],
pancreatic ductal adenocarcinoma [5], colorectal carcinoma [6],
gastric cancer stem cells [7], GIST [8], non-small cell lung
carcinoma [9], and head and neck cancer [10,11]. ADAM17 is
reported to have a direct functional role in controlling prolifer-
ation and/or migration of cells derived from many tumour types
[12,13,14,15,16,17,18,19,20], and it has been implicated in
controlling endothelial cell migration [21] and pathological
angiogenesis [22,23], which is also relevant to tumour growth.
ADAM17 can be activated by chemotherapy, resulting in growth
factor shedding, hence contributing to resistance in colorectal
cancer models [15,24]. ADAM17 may also contribute to resistance
to trastuzumab (HerceptinTM) in breast cancer [25]. Thus,
ADAM17 makes an attractive target for development of inhibitors,
which would have broad spectrum therapeutic potential in the
treatment of patients with cancer.
Small molecular inhibitors of ADAM17 have been developed
but none have yet shown complete specificity for ADAM17. For
example, INCB3619 and INCB7839 inhibit ADAM10, ADAM17
and matrix metalloproteinases MMP2, MMP12 and MMP15
[9,26,27,28]. The two ADAM17 inhibitors which have progressed
the furthest in development [29] are DPC 333 (BMS-561392) [30]
and TMI-005 (apratastat) [31]. These both show some inhibitory
activity against other MMPS and did not progress beyond Phase II
trial because of toxicity or lack of efficacy. Broad spectrum MMP
inhibitors (marimastat, prinomastat, tanomastat), that also inhibit
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the ADAMs, have not progressed beyond phase III clinical trials
due to lack of efficacy and significant toxicity [32,33,34,35],
suggesting that specificity is key when developing metalloprotei-
nase inhibitors.
A specific human ADAM17 inhibitory antibody, D1(A12), has
recently been developed, which inhibits the proteolysis of
ADAM17 substrates (TNF-a, AREG, etc.,) in cancer cells in vitro
[36]. The aim of the studies reported here was to assess the
suitability of the D1(A12) antibody for therapeutic use, by
investigating its pharmacokinetics, pharmacodynamics and anti-
tumour efficacy in mice. We chose to use the IGROV1-Luc model
of ovarian cancer, which has been reported to be TNF-a-
dependent [37].
High levels of expression of TNF-a have been observed in
ovarian carcinoma [38,39,40], particularly of the high grade
serous type [41], and an anti-TNF-a antibody, infliximab
(RemicadeTM), has been investigated for its efficacy against
ovarian cancer [42]. The IGROV1-Luc model is a human
tumour xenograft model of intraperitoneal disseminated ovarian
carcinoma. IGROV1-Luc cells secrete TNF-a and knockdown of
TNF-a expression by transfection of IGROV1-Luc cells with anti-
TNF-a shRNA was reported previously to inhibit tumour growth
[37]. Inhibition of ADAM17 by D1(A12) antibody was expected to
inhibit TNF-a secretion and thereby inhibit growth of IGROV1-
Luc tumours in vivo. For comparison, a group of mice were treated
with infliximab, which was expected to directly reduce functional
human TNF-a, also leading to inhibition of growth of the
IGROV1-Luc tumours.
Materials and Methods
Antibodies and chemicals
Isolation and purification of human anti-ADAM17 antibody
D1(A12) has been described previously [36]. Briefly, D1(A12) IgG
was expressed by transfection of HEK293 cells and conditioned
medium was collected. The antibody was purified from the
medium by chromatography on 2 protein L columns (Pierce)
followed by 2 Melon Gel columns (Pierce) and AKTA FPLC, and
then dialysed into sterile Phosphate Buffered Saline (PBS), pH 7.4
and filter-sterilised. Infliximab (RemicadeTM, Janssen Biotech
Inc.), a kind gift from Prof. Peter Taylor (Kennedy Institute of
Rheumatology), was dissolved in sterile saline. Control human
plasma IgG (R&D Systems 1-001-A) was used as a control in some
cell-based assays. N-TIMP-3 was prepared as described by Lee
et al [43]. Phorbol-12-myristate-13-acetate (PMA) was purchased
from Sigma, dissolved in DMSO to 25 mg/ml and diluted to
100 ng/ml in culture medium for assays.
Cell culture
The IGROV1 human ovarian cancer cell line [44] was infected
with a lentiviral vector containing a luciferase reporter construct
[37], and this IGROV1-Luc cell line was a kind gift from
Professors Fran Balkwill and Ian McNeish. The cells were grown
in RPMI-1640 medium containing 10% Fetal Bovine Serum. The
cell line tested negative for mycoplasma and the STR genotype
corresponded to that reported for IGROV1 cells in the NCI60
panel. Also, the reported p53 mutation (Y126C) was confirmed in
these cells by DNA sequencing.
Animal Studies
All mouse studies were performed in accordance with the UK
Animals (Scientific Procedures) Act 1986, under project licence
number 80/2346, with approval from the CRUK Cambridge
Research Institute Animal Ethics Committee and following
current UK Guidelines [45]. Balb/c nude female mice were
obtained from Charles River Laboratories and were used at 6–
10 weeks old (8 – 10 weeks for the PK study and 6 – 8 weeks for
the efficacy study). Mice were housed in groups in sterile
Individually Ventilated Cages. Mice were injected i.p. with
56106 IGROV1-Luc cells and were observed daily for tumour
growth and clinical signs. Tumour burden was quantified weekly
by bioluminescent imaging, as described below.
Both antibodies were diluted in sterile PBS, pH 7.4 for dosing
into mice at 10 mg/kg. For the PK study at least 2 mice per time
point were dosed i.p. with 10 mg/kg in a volume of 9.5 ml/kg.
The tumour-bearing mice were dosed for PK studies either
34 days after tumour implantation (for shorter time points), or
27 days after implantation for 7 – 9 day time points. The
concentrations of D1(A12) and infliximab in plasma, ascites fluid
and tumour homogenates were measured by quantitative ELISA
as described below. For the efficacy study the mice were
randomised into 3 groups and dosed i.v. with the antibodies at
10 mg/kg in a dose volume of 4.76 ml/kg, or with sterile PBS as a
vehicle control. The first dose was given on day 4 after tumour cell
injection, immediately after the first bioluminescent imaging
session, and every 7 days thereafter until day 32. On day 32 the
mice were imaged for the last time and given a final dose, then
they were killed the following day, day 33, 20 hours after the last
dose.
Blood was collected in lithium heparin tubes, centrifuged at
18,800 g for 5 minutes and plasma collected. Ascites fluid was
collected from the abdominal cavity and centrifuged at 18,800 g
for 5 minutes to remove any cells. Plasma and ascites fluid were
then snap-frozen and stored at 280uC. Organs and tumour were
collected post-mortem with part snap-frozen and part fixed in
Neutral Buffered Formalin (Sigma). Formalin-fixed tissues were
paraffin embedded, sectioned and stained with haematoxylin and
eosin. For analysis of tumour tissue by ELISA, weighed pieces of
frozen tissue (approximately 20 mg) were homogenised in MK-
28R tubes containing metal beads using a Precellys 24 homog-
eniser (Bertin Technologies, supplied by Stretton Scientific, UK) at
6000 rpm for 50 seconds, twice. The samples were homogenised
at a concentration of 50 mg of tissue per ml of buffer (PBS, pH 7.4
with added protease inhibitor cocktail (Sigma) and phosphatase
inhibitor cocktail 2 (Sigma) each diluted 1 in 100). The
homogenates were centrifuged at 10,000 g for 10 minutes at
4uC and the supernatant was used for ELISAs (see below).
Bioluminescent Imaging
Mice were anaesthetised using isoflurane then injected i.p. with
150 mg/g body weight D-Luciferin in PBS (Caliper Life Sciences)
and bioluminescent imaging with a charge-couple device camera
(IVIS 200, Xenogen, Alameda CA) was initiated 10 min after
injection. Images were obtained for groups of 3 mice with a 13 cm
field of view, binning (resolution factor) of 8 (medium), F stop = 1,
exposure = 1 to 10 seconds.
Data were analysed using Living Image 3.2 Software (Xenogen)
and presented as Average Radiance (units: photons/sec/cm2/
steradian) for each mouse, from a constant sized Region of Interest
drawn over the mouse abdomen. The mean and standard
deviation were expressed for each treatment group. Significance
between treated and vehicle groups was calculated using a t Test.
Quantitative ELISA
For both D1(A12) and infliximab human IgGs, ELISA plates
were coated with 50 ml/well 100 nM anti-human IgG (Abcam
ab700) in PBS. After washing with PBS-Tween (0.1% v/v) and
blocking with PBS-Milk (5% w/v), 50 ml of sample was added to
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each well (either 50 ml of plasma, tissue homogenate, or known
concentrations of D1(A12) or infliximab IgG for the standard
curves (0 – 1000 nM range, diluted in blank matrix (plasma or
tumour homogenate from untreated mice)). After incubation and
washing the human IgG was detected by incubating with anti-
human-kappa light chain-HRP antibody (Bethyl A80-115P)
(1:2000 in PBS-milk), followed, after washing, by 50 ml of
3,39,5,59-tetremethylbenzidine (TMB) incubated at room temper-
ature for 2 mins then quenched with 50 ml 1M HCl. Absorbance
was measured at 450 nm. Pharmacokinetic parameters were
calculated using a non-compartmental model in WinNonlin v5.1
(Pharsight).
ELISAs for ADAM17 substrates were performed using R&D
Systems Duoset kits: human TNF-a (TNFSF1A, cat. No. DY210),
human soluble TNFR1-a (TNFRSF1A, cat. No. DY225), human
TGF-a (cat. No. DY239), human AREG (cat. No. DY262),
human IL-6Ra (cat. No. DY227) and human HB-EGF (DY259).
The DY210 kit was confirmed to be specific for human TNF-a by
testing recombinant mouse TNF-a with this kit, there was no
cross-reactivity.
Where tumour homogenates were used, raw nM concentrations
in homogenate solution were converted to nmoles per mg tissue,
and then using the assumption that tissue density is 1 g/ml, the
molar concentration in tissue was calculated.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, par-
affin-embedded sections of tumour and liver after antigen retrieval
by enzyme digestion (proteinase k) at 37uC for 10 minutes. The
human IgG with which the mice had been dosed (D1(A12) or
infliximab) was detected by binding of a Biotin-SP-conjugated
AffiniPure F(ab’)2 fragment donkey anti-human IgG (H+L)
(Jackson ImmunoResearch Laboratories, Inc.), followed by stain-
ing with DAB+ chromogen. Slides were scanned using a
ScanScopeXT (Aperio Technologies, Inc.) at 20X magnification
and scanned images were viewed using Spectrum v10 software
(Aperio Technologies Inc). No image manipulation was per-
formed.
Results
Effect of D1(A12) antibody in IGROV1-Luc cells in vitro
IGROV1-Luc tumour cells in vitro secreted TNF-a, TNFR1-a,
TGF-a, AREG, HB-EGF and IL-6Ra, all known substrates for
the shedding activity of ADAM17, into the culture medium even
when unstimulated (Figure 1A). When stimulated with PMA the
concentrations of these proteins shed into the medium increased at
least 5-fold (apart from IL-6R a, 2.7-fold increase). This PMA-
stimulated increase was inhibited by the addition of 200 nM
D1(A12) IgG (Figure 1A). The inhibition of TNF-a shedding by
D1(A12) was dose-dependent, with an IC50 in IGROV cells of
4.7 nM (Figure 1B). D1(A12) was a more potent inhibitor of TNF-
a shedding than N-TIMP-3 (IC50 of 72 nM), a natural
metalloproteinase inhibitor previously shown to inhibit ADAM17
[43]. D1(A12) IgG also inhibited constitutive shedding of TNF-a
into the medium over a longer period (Figure 1C). D1(A12) did not
inhibit proliferation of IGROV1-Luc cells in vitro in the presence of
normal growth medium (data not shown), which is consistent with
the effect of the TNF-a shRNA on IGROV1-Luc cells as
previously reported [37].
IGROV1-Luc Tumour growth in vivo
The IGROV1-Luc cells grew and disseminated intraperitone-
ally in nude mice (Figure 2A), as previously reported [37], with
individual tumour masses showing a histological appearance
consistent with human high grade serous ovarian adenocarcinoma
(M. Jimenez-Linan, personal communication). The largest deposits
of tumour were in the pancreas, omentum and mesentery of all
mice. By the endpoint around day 32 – 35, the tumour-bearing
mice had developed peritoneal exudate (ascites fluid). Human
TNF-a, TNFR1-a, TGF-a, amphiregulin (AREG), and HB-EGF
(ADAM17 substrates) were detected in the circulation of
IGROV1-Luc tumour-bearing mice, with high concentrations in
the ascites fluid and lower concentrations in the plasma (as shown
in the vehicle control groups of the efficacy study, shown later).
Pharmacokinetics of D1(A12) IgG
The pharmacokinetics (PK) of D1(A12) antibody were investi-
gated using a single 10 mg/kg dose i.p., in non-tumour-bearing
mice (Figure 2B). PK parameters were calculated for non-tumour-
bearing mice using the WinNonLin noncompartmental analysis
programme: plasma Cmax = 523+/258 nM, Tmax 2 days, half life
8.6 days. More limited sampling was then performed in mice
bearing IGROV1-Luc tumours (Figure 2C), in which the D1(A12)
IgG showed similar kinetics to the non-tumour bearing mice. After
a 10 mg/kg dose i.p. the Cmax was 425+/251 nM in plasma and
391+/219 nM in ascites fluid, lower than the plasma Cmax in the
mice without tumours. These data were sufficient to predict that
circulating D1(A12) concentrations of above 100 nM can be
maintained by dosing 10 mg/kg once every 7 days. 100 nM
D1(A12) is sufficient concentration to cause maximal inhibition of
ADAM17 function in IGROV1 cell culture (Figure 1B).
The detection of D1(A12) antibody by ELISA does not
necessarily mean that the antibody had retained its activity, as it
could be partially denatured, so the binding activity of the plasma
D1(A12) antibody was assessed (Figure 2D and Figure S1). The
D1(A12) antibody from the plasma of mice at all time points from
1 to 9 days retained the ability to bind ADAM17 (100% at day 9,
compared to the D1(A12) stock solution). In contrast, the ability of
D1(A12) to bind to human FccR1 decreased with time, with
binding after 9 days in the mouse only 32% of the binding of
D1(A12) stock solution.
Efficacy studies and pharmacodynamics
Having established that the D1(A12) antibody has suitable PK
characteristics, we tested the effect of weekly dosing in IGROV1-
Luc xenografts with 10 mg/kg D1(A12) (n = 11), in comparison
with 10 mg/kg infliximab (n= 8) and PBS vehicle (n = 12). Prior to
the first dose on day 4 after cell injection there was no significant
difference in the tumour burden between the groups: Avg
Radiance (x 106 p/s/cm2/Sr) 2.71+/21.35, 2.92+/21.23 and
2.65+/20.91 for vehicle, infliximab and D1(A12) groups, respec-
tively. Tumour size at the endpoint on day 32 is presented in
Figure 3. The D1(A12) group had a significantly smaller tumour
burden (Avg Radiance x 106 p/s/cm2/Sr) on day 32 of 23.3+/
29.1 compared to the vehicle group (41.8+/217.2, p = 0.005).
The mean tumour burden in the D1(A12) group at the endpoint
was 56% of the vehicle control. In contrast there was no inhibition
of tumour growth in mice treated with infliximab compared to
vehicle, with the tumour burden of 39.1+/211.6 in the infliximab
group (p = 0.68).
To confirm that therapeutic concentrations of antibody had
been achieved, the concentration of D1(A12) and infliximab was
determined in the plasma and ascites fluid (Figure 4A) and in
tumour homogenates (Figure 4B). As expected, no human IgG was
detected in any of the samples from the vehicle-treated group.
D1(A12) and infliximab were present at high concentrations in
plasma and ascites fluid in the appropriate treatment group, and
Anti-ADAM17 Antibody in an Ovarian Cancer Model
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both antibodies were detectable in tumour from both pancreas
and omentum. The concentration of D1(A12) was higher in
tumour than infliximab, but infliximab was higher in plasma and
ascites fluid than D1(A12).
To investigate the distribution of D1(A12) and infliximab in the
tumour tissue, anti-human IgG immunohistochemistry was
performed on paraffin sections from the tumours (Figure 4C).
The two therapeutic antibodies were detectable as strong IHC
staining in the liver, and both were also detectable in the tumour
tissue, but the distribution appeared to be confined to the blood
vessels.
To determine whether either antibody had pharmacodynamic
effects we analysed the concentrations in plasma and ascites fluid
of the products of ADAM17 sheddase activity, i.e. soluble human
TNF-a, soluble TNFR1-a, TGF-a and amphiregulin (AREG)
(Figure 5). All four of the proteins analysed showed significantly
higher concentrations in ascites fluid than in plasma. As expected,
there was a significant reduction in sTNF-a in the ascites fluid of
infliximab-treated mice when compared to vehicle (3.7-fold
reduction, p,0.0001). Surprisingly, there was no significant
reduction in sTNF-a in the D1(A12)-treated mice (P= 0.06).
However, D1(A12) did show clear pharmacodynamic effects by
significantly reducing the ascites fluid concentrations of soluble
TNFR1-a (4.4-fold reduction, P,0.0001), AREG (5.4-fold reduc-
tion, P,0.0001) and TGF-a (15-fold reduction, P,0.0001).
D1(A12) also reduced significantly the plasma concentrations of
soluble TNFR1-a (P,0.0001), AREG (P=0.012) and TGF-a
(P = 0.005).
Discussion
We have investigated the biological activity of D1(A12), a
monoclonal antibody specific for human ADAM17, which inhibits
ADAM17 function by cross-domain inhibition of the ectodomain.
We have demonstrated that the antibody (at nanomolar concen-
trations) inhibits shedding of ADAM17 substrates including TNF-
a and AREG in IGROV1-Luc cells in vitro.
The PK properties of the D1(A12) IgG in mice were found to be
suitable for efficacy studies. The plasma half life is consistent with
published values for the half life of human IgG antibodies in
Figure 1. In vitro activity of D1(A12) antibody. (A) D1(A12) IgG inhibits PMA-induced shedding of ADAM17 substrates into IGROV1-Luc cell
culture medium. Medium was collected 90 minutes after addition of PMA (100 ng/ml), D1(A12) IgG (200 nM) or solvent control. The proteins were
quantified by ELISA. (B) Dose-dependent inhibition of TNF- a shedding by 1 hour pretreatment with D1(A12), N-TIMP-3 or control human plasma IgG
prior to PMA stimulation. (C) D1(A12) IgG inhibits constitutive shedding of TNF-a from IGROV1-Luc cells into culture medium. Medium was collected
after 48 hours of incubation with or without IgGs at 200 nM. Error bars show the standard deviation.
doi:10.1371/journal.pone.0040597.g001
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mouse plasma [46]. The plasma and ascites Cmax were lower in
the tumour bearing mice than the plasma Cmax in the mice
without tumours. However, this is not surprising given the larger
total body fluid volume in the tumour-bearing mice due to the
ascites fluid compartment. The plasma and ascites fluid concen-
trations of D1(A12) IgG were very similar within each individual
mouse, from both the PK and efficacy studies, suggesting that the
antibody is able to equilibrate between these two compartments
after either IP or IV dosing. We have demonstrated that D1(A12)
antibody is structurally stable in the mouse circulation, retaining
the ability to bind to human ADAM17 up to 9 days after dosing.
However, the ability of D1(A12) to bind to human FccR1
decreased with time in the mouse plasma, such that only 32% of
the binding activity remained after 9 days in the mouse. The
reduced FccR1 binding capacity may be due to soluble Fc-
receptors present in mouse serum. For example, mouse FcRn
binds human IgG1 with high affinity [47] and is responsible for the
long in vivo half-life of antibodies [48].
The PK properties and stability of D1(A12) IgG in the mouse
circulation indicated that weekly dosing should maintain concen-
trations high enough to be biologically active in vivo, so efficacy
studies were performed in the IGROV1-Luc model. D1(A12)
antibody showed anti-tumour effects, with the tumour burden at
the end of the study approximately 56% of the vehicle control
group. This was a modest anti-tumour effect, and some possible
explanations for this are discussed below.
Tumour homogenates had concentrations of D1(A12) IgG
above the cellular IC50, but analysis by IHC showed limited
penetration beyond the tumour blood vessels. Similar limited
penetration has been observed in xenograft tumours for the high
affinity anti-HER2 antibody trastuzumab [49], which is neverthe-
less an effective drug in vivo. Distribution of monoclonal antibodies
Figure 2. The IGROV1-Luc xenograft model and D1(A12) pharmacokinetics. (A) Example of the growth of IGROV1-Luc intraperitoneal
tumour, as measured by bioluminescence, from 11 to 29 days after injection of the cells. (B and C) Pharmacokinetics of D1(A12) in nude mice after a
single dose of 10 mg/kg i.p. N= 2 or more mice per time point. Error bars represent the standard error of the mean (B) Plasma concentrations in non-
tumour-bearing mice. (C) Plasma and ascites fluid concentrations in IGROV1-Luc tumour-bearing mice. (D) D1(A12) IgG in mouse plasma: capacity for
binding to ADAM17 and FccR1. Plasma was collected at the indicated times after dosing the mice with a single dose of 10 mg/kg D1(A12). Binding
activity in vitro was compared to the binding capacity of D1A12 stock solution. Error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0040597.g002
Figure 3. Inhibition of IGROV1-Luc tumour growth in vivo by
D1(A12) IgG. Growth of IGROV1-Luc i.p. xenografts in mice dosed
weekly with vehicle, 10 mg/kg infliximab or 10 mg/kg D1(A12),
measured by bioluminescence. The mean and standard deviation of
day 32 tumour burden is shown, expressed as Avg Radiance. N= 12 for
vehicle, n = 8 for infliximab and N= 11 for D1(A12).
doi:10.1371/journal.pone.0040597.g003
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into tumour tissue has been shown to be limited by penetration
through capillary walls and also by additional factors once the
antibody has crossed the blood vessel wall [50]. Penetration of
D1(A12) may be better in tumours with more permeable vessels
than those in the IGROV1 tumours. However, limited tumour
penetration of D1(A12) IgG in the IGROV1-Luc tumours did not
prevent the antibody causing clear pharmacodynamic effects
(shedding of ADAM17 substrates, see below). Interestingly,
D1(A12) concentration was higher in tumour than infliximab,
but lower in plasma and ascites fluid than infliximab, perhaps
Figure 4. Distribution of D1(A12) and infliximab IgG in vivo at the end of the efficacy study. Samples were taken at endpoint (day 33),
20 hours after the final antibody dose. (A) Concentrations in plasma and ascites fluid. Horizontal bars represent the mean and standard deviation. (B)
Concentrations in homogenates of tissue from tumour in pancreas and omentum. (C) Immunohistochemistry to detect human IgG in IGROV1-Luc
tumour and liver. Top: mouse ID 901, treated with D1(A12), with an arrow marking the position of a blood vessel; middle: mouse ID 903, treated with
infliximab; bottom: mouse ID 902, treated with vehicle. Images were taken at 20X magnification.
doi:10.1371/journal.pone.0040597.g004
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reflecting the location of the target for each antibody (ADAM17 at
the tumour cell plasma membrane, versus circulating TNF-a
which is present at high concentrations in the plasma and ascites).
To determine whether the antibodies were hitting their targets
and having pharmacodynamic effects, ELISA assays of ADAM17
substrates were performed on plasma and ascites fluid samples at
the end of the efficacy study. Vehicle-treated mice showed much
higher concentrations of soluble TNF-a, TNFR1-a, AREG and
TGF-a in ascites fluid than in plasma, suggesting that these
proteins do not freely equilibrate between the plasma and ascites
compartments, in contrast to the dosed IgGs which did equilibrate
between the compartments.
Comparison of the D1(A12) treated group with the vehicle
controls showed that D1(A12) did significantly inhibit shedding of
ADAM17 substrates, the EGFR ligands TGF-a and AREG, and
TNFR1-a. However, D1(A12) did not significantly inhibit TNF-a
shedding in vivo, which was surprising because TNF-a shedding
was inhibited by D1(A12) in the IGROV1-Luc cells in vitro. The
lack of inhibition of TNF-a shedding in vivo might explain the
relatively modest antitumour effect of the antibody, because TNF-
a was thought to be a key driver of tumour growth in this model,
based on the shRNA work of Kulbe, et al [37], but the infliximab
data confounds this hypothesis (see below).
ADAM17 has been considered the key enzyme responsible for
shedding of TNF-a, but our results with the D1(A12) antibody
suggest that another enzyme may compensate when ADAM17
activity is inhibited in IGROV1-Luc cells grown in vivo (but not in
vitro). This may be ADAM10: ADAM10 has shown TNF-a
sheddase activity in ADAM17-deficient murine fibroblasts [51]
and has been implicated in TNF-a production in mantle cell
lymphoma [52]. Also, Hikita et al [53] showed that while
ADAM17 is indeed the major TNF-a sheddase in macrophages,
ADAM10 is also a TNF-a sheddase in adenovirus-transformed
human embryo kidney 293A cells, NIH3T3 mouse embryo
fibroblasts and murine endothelial cells. Also, when overexpressed,
ADAM19 may be capable of contributing to TNF-a shedding
[54]. These data suggest that for inhibition of TNF-a shedding
from tumours in vivo, inhibition of both ADAM17, ADAM10 and
ADAM19 may be required. In the in vivo studies the tumour cells
would have been exposed to D1(A12) for 28 days, and if the
compensatory mechanisms were slow to develop, this could
explain why this compensation was not observed in the in vitro
assays which were performed over 48 hours or less. Another
Figure 5. Inhibition of shedding of ADAM17 substrates by D1(A12) and infiximab. Concentrations of the cleaved products of ADAM17
substrates in plasma and ascites fluid at the endpoint (day 33), as measured by ELISA. Horizontal bars represent the mean and standard deviation.
Asterisks show the groups significantly different (P,0.05) from the PBS control group in the same fluid type.
doi:10.1371/journal.pone.0040597.g005
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possible explanation for the lack of inhibition of TNF-a shedding
in vivo is that shedding in trans could be occurring, where murine
ADAM17 on host cells, which would not be regulated by D1(A12),
could cleave TNF-a on adjacent human tumour cells. To our
knowledge trans-shedding has not been reported for ADAM17,
but it has for ADAM10 cleavage of ephrin A5 [55]. This would
suggest that TNF-a shedding was confined to highly active regions
of host-tumour interaction such as at the invading margins.
Whatever the mechanism for the sustained shedding of TNF-a in
vivo, it is striking that shedding of the other ADAM17 cleavage
products were inhibited by D1(A12). It is possible that the
difference relates to the type of transmembrane proteins involved:
pro-TNF-a is a Type II transmembrane protein, whose C-
terminus is extracellular, whereas pro-AREG and the other EGFR
ligands are Type I transmembrane proteins, whose N-termini are
extracellular. This might confer a difference in specificity for other
metalloproteinases in certain contexts, or the ability to be a
substrate for shedding in trans. Another possible explanation for
the difference between the ADAM17 substrates is that TNF-a
shedding might occur deeper within the tumour mass (where
antibody penetration may be limiting) than the shedding of the
EGFR ligands. If the D1(A12) was unable to inhibit TNF-a
shedding by ADAM17 deep in the tumour this pharmacokinetic
feature could also explain the discrepancy between the in vitro and
in vivo studies, as the cells in vitro would all be exposed to the
antibody.
We used the specific human TNF-a antibody infliximab in our
efficacy studies as a positive control, expecting it to inhibit growth
of IGROV1-Luc tumours. TNF-a shedding was significantly
inhibited in the infliximab group compared to the vehicle, but
surprisingly infliximab did not inhibit tumour growth, in contrast
to the published study showing that TNF-a shRNA knockdown
did inhibit IGROV1-Luc tumour growth in vivo [37]. What could
be the explanation for the difference between antibody and
shRNA? With the shRNA the TNF-a was knocked down before
the cells were implanted into the mice, whereas with our antibody
efficacy study the TNF-a was knocked down only after the tumour
had established in the mice, 4 days after implantation, so it is
possible that TNF-a is required for the establishment of the
tumour but not thereafter. However, we have pre-treated cells
with infliximab prior to implantation and started dosing with
infliximab at the time of implantation and this still did not inhibit
tumour initiation or subsequent growth (data not shown). Another
possibility is that endogenous mouse TNF-a was able to
compensate for reduced human TNF-a in the infliximab-treated
mouse model, because it is known that mouse TNF-a can bind
human TNFR1 and TNFR2 [56]. However, Salako, et al., have
recently confirmed that infliximab did not reduce tumour growth
in this IGROV1 model, even when co-administered with an anti-
mouse TNF-a antibody [57]. Thus, signalling by murine TNF-a is
unlikely to explain the difference in antitumour activity between
knockdown of TNF-a protein levels and the knockdown by
shRNA. It is possible that other factors could compensate for the
infliximab-induced reduction in TNF-a, but we would expect that
these compensating factors would also have counteracted the effect
of TNF-a knockdown, and that was not observed in the studies by
Kulbe, et al [37]. As well as paracrine signalling by soluble TNF-
a, juxtacrine signalling by transmembrane proTNF-a has been
reported in a variety of cell types [58,59,60]. However, infliximab
can effectively inhibit both soluble and transmembrane TNF-a
[61] and should therefore inhibit juxtacrine signalling also. It is
possible that the limited penetration of infliximab into the tumour
tissue resulted in active transmembrane TNF-a remaining deep in
the tissue, which continued to signal in a juxtacrine manner and
supported tumour growth, even when infliximab had reduced the
concentration of circulating sTNF-a. This could explain the
discrepancy between the infliximab and siRNA results and
between the in vitro and in vivo results.
While inhibition of ADAM17 by D1(A12) did not significantly
inhibit TNF-a shedding it did efficiently inhibit shedding of other
ADAM17 substrates, the EGFR ligands TGF-a and AREG,
suggesting that other ADAMs do not compensate for loss of
ADAM17 activity on these proteins in vivo. Thus, the D1(A12)
specific ADAM17 inhibitor which showed modest antitumour
effects in the IGROV1-Luc model may show more effective
antitumour activity in tumours that are dependent on EGFR
ligand signalling.
Supporting Information
Figure S1 Analysis of the binding capacity of the
D1(A12) IgG in mouse plasma. Each line represents the
plasma from one mouse, taken from the tumour-bearing mice used
in the PK study (ID number 809 to 820, with the timepoint in days
shown in parentheses). Using the D1(A12) plasma IgG concen-
trations as determined in Figure 2C, the IgG was diluted to
different concentrations and tested for binding by ELISA. (A)
Binding to a control anti-human IgG, to confirm the dilutions of
plasma D1(A12) are correct. (B) Binding to ADAM17. (C) Binding
to human FccR1.
(TIF)
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